Literature DB >> 15942443

Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases.

Carmela Loguercio1, Alessandro Federico, Concetta Tuccillo, Fulvia Terracciano, Mauro Valeriano D'Auria, Claudio De Simone, Camillo Del Vecchio Blanco.   

Abstract

OBJECTIVES: To evaluate whether chronic therapy with probiotics affects plasma levels of cytokines and oxidative/nitrosative stress parameters, as well as liver damage, in patients with various types of chronic liver disease. PATIENTS AND METHODS: A total of 22 nonalcoholic fatty liver disease (NAFLD) and 20 alcoholic liver cirrhosis (AC) patients were enrolled in the study and compared with 36 HCV-positive patients with chronic hepatitis without (20, CH) or with (16, CC) liver cirrhosis. All patients were treated with the probiotic VSL#3. Routine liver tests, plasma levels of tumor necrosis factor alpha (TNF-alpha), interleukin (IL)-6 and -10, malondialdehyde (MDA), and 4-hydroxynonenal (4-HNE), S-nitrosothiols (S-NO), were evaluated on days -30, 0, 90, and 120.
RESULTS: Treatment with VSL#3 exerted different effects in the various groups of patients: in NAFLD and AC groups, it significantly improved plasma levels of MDA and 4-HNE, whereas cytokines (TNF-alpha, IL-6, and IL-10) improved only in AC patients. No such effects were observed in HCV patients. Routine liver damage tests and plasma S-NO levels were improved at the end of treatment in all groups.
CONCLUSIONS: Results of the study suggest that manipulation of intestinal flora should be taken into consideration as possible adjunctive therapy in some types of chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942443     DOI: 10.1097/01.mcg.0000165671.25272.0f

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  135 in total

Review 1.  Fighting fire with fire: is it time to use probiotics to manage pathogenic bacterial diseases?

Authors:  John Heineman; Sara Bubenik; Stephen McClave; Robert Martindale
Journal:  Curr Gastroenterol Rep       Date:  2012-08

Review 2.  Alcoholic liver disease: the gut microbiome and liver cross talk.

Authors:  Phillipp Hartmann; Caroline T Seebauer; Bernd Schnabl
Journal:  Alcohol Clin Exp Res       Date:  2015-05       Impact factor: 3.455

3.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

4.  Current status of therapy in nonalcoholic Fatty liver disease.

Authors:  Scott McNear; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

5.  Targeting the gut barrier for the treatment of alcoholic liver disease.

Authors:  Zhanxiang Zhou; Wei Zhong
Journal:  Liver Res       Date:  2017-12

Review 6.  Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Kazuhiro Kotoh; Manabu Nakashima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  Diagnosis and management of bacterial infections in decompensated cirrhosis.

Authors:  Maria Pleguezuelo; Jose Manuel Benitez; Juan Jurado; Jose Luis Montero; Manuel De la Mata
Journal:  World J Hepatol       Date:  2013-01-27

Review 9.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 10.  Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis.

Authors:  Jacquelyn J Maher; Pablo Leon; James C Ryan
Journal:  Hepatology       Date:  2008-08       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.